There are currently 1875 clinical trials in Philadelphia, Pennsylvania looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Pennsylvania, Children's Hospital of Philadelphia, Fox Chase Cancer Center and Thomas Jefferson University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT06388421
Recruiting
This is a prospective, non-interventional, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Thomas Jefferson University - Sidney Kimmel Medical College, Philadelphia, Pennsylvania +1 locations
Conditions: Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
Register for Updates
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
NCT06980805
Recruiting
The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of IMVT-1402 in participants with Cutaneous Lupus Erythematosus. The study will consist of 3 periods: Period 1: eligible participants will be randomized 1:1 to IMVT-1402 or placebo SC QW for 12 weeks. Period 2: participants who completed Period 1 will receive IMVT-1402 SC QW for 14 weeks. Period 3: after completion of Period 2, participants will be re-randomized 1:1 to blinded IMVT-1402 SC QW for 26 weeks... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Site Number - 1015, Philadelphia, Pennsylvania
Conditions: Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Register for Updates
Childhood Cancer Survivor Study
NCT01120353
Recruiting
The Childhood Cancer Survivor Study (CCSS) will investigate the long-term effects of cancer and its associated therapies. A retrospective cohort study will be conducted through a multi-institutional collaboration, which will involve the identification and active follow-up of a cohort of approximately 50,000 survivors of cancer, diagnosed before 21 years of age, between 1970 and 1999 and 10,000 sibling controls. This project will study children and young adults exposed to specific therapeutic mod... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/07/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Cancer
Register for Updates
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
NCT03093116
Recruiting
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blin... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/07/2025
Locations: Local Institution - 2108, Philadelphia, Pennsylvania
Conditions: Locally Advanced Solid Tumors, Metastatic Solid Tumors
Register for Updates
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
NCT03331198
Recruiting
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or SLL, followed by a Phase 2 part to further assess the efficacy and safety of JCAR017 monotherapy treatment at the recommended dose. A separate Phase 1 cohort will assess the combination of JCAR017 and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: University of Pennsylvania - Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania +3 locations
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
Register for Updates
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
NCT04416568
Recruiting
This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.
Gender:
ALL
Ages:
Between 6 months and 40 years
Trial Updated:
07/07/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Malignant Rhabdoid Tumor, Rhabdoid Tumor of the Kidney, Epithelioid Sarcoma, Chordoma (Poorly Differentiated or De-differentiated), Atypical Teratoid/Rhabdoid Tumor, Other INI1 Negative Tumors (With PI Approval), Other SMARCA4-deficient Malignant Tumors (With PI Approval)
Register for Updates
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562
Recruiting
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.
Gender:
ALL
Ages:
All
Trial Updated:
07/07/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania +1 locations
Conditions: H3 K27M, Glioma
Register for Updates
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
NCT05651932
Recruiting
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Multiple Myeloma, Myeloma, Myeloma Multiple
Register for Updates
TSC Biosample Repository and Natural History Database
NCT05676099
Recruiting
The TSC Biosample Repository collects and stores samples of blood, DNA, and tissues that scientists can request to use in their research. The samples we collect are all linked to clinical data in the TSC Natural History Database. The TSC Natural History Database captures clinical data to document the impact of the disease on a person's health over his or her lifetime. This data may be collected retrospectively or prospectively.
Gender:
ALL
Ages:
All
Trial Updated:
07/07/2025
Locations: University of Pennsylvania Medical Center, Philadelphia, Pennsylvania
Conditions: Tuberous Sclerosis, Lymphangioleiomyomatosis
Register for Updates
Parasitic Ulcer Treatment Trial
NCT06213649
Recruiting
The Parasitic Ulcer Treatment Trial (PUTT) is a multi-center, parallel-group, randomized clinical trial. The purpose of this study is to determine whether including topical corticosteroids in a regimen for acanthamoeba keratitis (AK) will improve vision. Patients presenting to all enrollment centers with evidence of acanthamoeba keratitis will be eligible for the trial if there is evidence of ocular inflammation after 4 weeks of anti-amoebic therapy. Those who agree to participate will be random... Read More
Gender:
ALL
Ages:
8 years and above
Trial Updated:
07/07/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Acanthamoeba Keratitis
Register for Updates
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B)
NCT06349473
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in healthy participants (Part A) and to evaluate the safety, tolerability, PK, PD, and efficacy of SR604 in participants with Hemophilia A or Hemophilia B, with or without inhibitors (Part B).
Gender:
MALE
Ages:
Between 18 years and 60 years
Trial Updated:
07/07/2025
Locations: Perelman Center for Advanced Medicine (PCAM)- Penn Blood Disorders Program, Philadelphia, Pennsylvania
Conditions: Healthy Participants, Hemophilia A, Hemophilia B
Register for Updates
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
NCT06377852
Recruiting
The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 65 years) tolerate side effects and stay on treatment longer, to derive the most clinical benefit from these drugs. The primary objective of the CDK Study is to compare time to treatment discontinuation (TTD) on the approved dosing for palbociclib (125 mg orally daily on days 1-21 of 28-day cycle) or ribociclib (600 mg orally... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/07/2025
Locations: Penn Medicine - Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania +1 locations
Conditions: Metastatic Breast Cancer
Register for Updates